Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

Trial Details

NCT ID

NCT06218914

Phase

PHASE1

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

NT-112: Autologous, engineered T Cells targeting KRAS G12D
AZD0240: Autologous, engineered T Cells targeting KRAS G12D

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Los Angeles, California, United States|34.05223,-118.24368
Newport Beach, California, United States|33.61891,-117.92895
Jacksonville, Florida, United States|30.33218,-81.65565
Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Age ≥18 years
Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma, Endometrial Cancer or any other solid tumor
Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\*08:02 positive, HLA-A\*11:01 or HLA-A\*11:02 positive in at least one al…
Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease (Stage III or IV) after at least 1 line of approved…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →